Data on its safety profile remain limited, and further controlled research is needed to define potential risks and tolerability
Publication bias of the included studies suggested a large symmetry whose interpretation is inherently limited due to the small number of studies and was assessed using funnel plots, highlighting the need for the implementation of other formal statistical tests for funnel plot asymmetry, such as Eggers test or Beggs test
Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
When the GSSG form is ten times as great to the GSH form, the cell is exposed to oxidative stress (Rushworth and Megson, 2014)
These vials are tested for purity and come with a Certificate of Analysis (COA) for verification.
The ability to cross the rat placenta has been described as low and very limited for sotagliflozin and empagliflozin respectively
